Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) - A Cost-Utility Model for the United Kingdom

Value Health. 2014 Nov;17(7):A382. doi: 10.1016/j.jval.2014.08.2626. Epub 2014 Oct 26.

Authors

D Harland¹, B Naisbett-Groet¹, S Chang², D K Sungher³, L Sawyer², A Diamantopoulos⁴

Affiliations

¹ Roche Products Limited, Welwyn Garden City, UK.
² Symmetron Limited, Herts, UK.
³ Symmetron Limited, Elstree, UK.
⁴ Symmetron Limited, Borehamwood, UK.

PMID: 27200855
DOI: 10.1016/j.jval.2014.08.2626

No abstract available